Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Active-site directed irreversible inhibitors of dihydrofolate reductase.

× No keyword cloud information.

8 in total

1. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.

Authors: L C Chio; S F Queener
Journal: Antimicrob Agents Chemother Date: 1993-09 Impact factor: 5.191

Review 2. Migraine.

Authors: Michel D Ferrari; Peter J Goadsby; Rami Burstein; Tobias Kurth; Cenk Ayata; Andrew Charles; Messoud Ashina; Arn M J M van den Maagdenberg; David W Dodick
Journal: Nat Rev Dis Primers Date: 2022-01-13 Impact factor: 52.329

3. Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue.

Authors: Wentao Chen; Jiajia Dong; Lars Plate; David E Mortenson; Gabriel J Brighty; Suhua Li; Yu Liu; Andrea Galmozzi; Peter S Lee; Jonathan J Hulce; Benjamin F Cravatt; Enrique Saez; Evan T Powers; Ian A Wilson; K Barry Sharpless; Jeffery W Kelly
Journal: J Am Chem Soc Date: 2016-06-02 Impact factor: 15.419

4. Clinical, toxicological, and pharmacological studies of combination chemotherapy of adenocarcinoma with adriamycin and Baker's antifolate.

Authors: S W Hall; T F Tenczynski; R S Benjamin; M A Burgess; M Valdivieso; T L Loo; G P Bodey
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

5. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.

Authors: J C Arseneau; B Bundy; H Homesley; J Beecham
Journal: Invest New Drugs Date: 1983 Impact factor: 3.850

Active-site directed irreversible inhibitors of dihydrofolate reductase.

1. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase.

Review 2. Migraine.

3. Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue.

4. Clinical, toxicological, and pharmacological studies of combination chemotherapy of adenocarcinoma with adriamycin and Baker's antifolate.

5. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study.

6. SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization.

7. Central nervous system pharmacology of Baker's antifolate (NSC139105) in man.

Review 8. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal.